Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

por Ghia, Paolo, Coutre, Steven E., Cheson, Bruce D., Barrientos, Jacqueline C., Hillmen, Peter, Pettitt, Andrew R., Zelenetz, Andrew D., Shreay, Sanatan, Hallek, Michael, Furman, Richard R.
Publicado 2020

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

por Coutre, Steven E, Barnett, Christopher, Osiyemi, Olayemi, Hoda, Daanish, Ramgopal, Moti, Fort, Alexander C, Qaqish, Roula, Hu, Yiran, Ninomoto, Joi, Alami, Negar N, Styles, Lori, Treon, Steven P
Publicado 2022

Management of adverse events associated with idelalisib treatment: expert panel opinion

por Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Publicado 2015

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

por Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Publicado 2018

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

por Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Publicado 2019

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

por Chen, Christine, Reece, Donna E, Siegel, David, Niesvizky, Ruben, Boccia, Ralph V, Stadtmauer, Edward A, Abonour, Rafat, Richardson, Paul, Matous, Jeffrey, Kumar, Shaji, Bahlis, Nizar J, Alsina, Melissa, Vescio, Robert, Coutre, Steven E, Pietronigro, Dennis, Knight, Robert D, Zeldis, Jerome B, Rajkumar, Vincent
Publicado 2009

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

por Burger, Jan A., Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Tedeschi, Alessandra, Bairey, Osnat, Hillmen, Peter, Coutre, Steven E., Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Simpson, David, Offner, Fritz, Moreno, Carol, Dai, Sandra, Lal, Indu, Dean, James P., Kipps, Thomas J.
Publicado 2019

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

por Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O’Brien, Susan M., Stilgenbauer, Stephan
Publicado 2019

Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

por Robak, Tadeusz, Burger, Jan A., Tedeschi, Alessandra, Barr, Paul M., Owen, Carolyn, Bairey, Osnat, Hillmen, Peter, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven E., Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A., Moreno, Carol, Gill, Devinder S., Flinn, Ian W., Gribben, John G., Mokatrin, Ahmad, Cheng, Mei, Styles, Lori, James, Danelle F., Kipps, Thomas J., Ghia, Paolo
Publicado 2018

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

por Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie‐Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, Burger, Jan A.
Publicado 2018

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

por Shanafelt, Tait D., Wang, Xin Victoria, Hanson, Curtis A., Paietta, Elisabeth M., O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong Christine, Coutre, Steven E., Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin, Kay, Neil E.
Publicado 2022